-
Mashup Score: 30Registration is open! 12th ESUR Prostate MRI - 2 month(s) ago
Data Protection InformationResponsible: THEORIA CONGRESOS (Hernández Tena Congresos S.L; Purpose: to provide you with the services you have requested, attend your requests for information and send you commercial communications; Legitimation: Execution of contract, Legitimate interest of the responsible or Consent of the Interested Party. Transfers: Your data will not be transferred to third…
Source: 7s7y.mjt.luCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14The association between patient and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance - 2 month(s) ago
World Journal of Urology – The objective of this study was to identify and assess patient and disease characteristics associated with an increased risk of disease progression in men with prostate…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Registration is open! 12th ESUR Prostate MRI - 3 month(s) ago
Data Protection InformationResponsible: THEORIA CONGRESOS (Hernández Tena Congresos S.L; Purpose: to provide you with the services you have requested, attend your requests for information and send you commercial communications; Legitimation: Execution of contract, Legitimate interest of the responsible or Consent of the Interested Party. Transfers: Your data will not be transferred to third…
Source: 7s7y.mjt.luCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
Objectives To quantify extraprostatic findings (EPFs) on prostate MRI, estimate the proportion of reported and unreported EPFs, assess their clinical importance, and propose standardized reporting of EPFs. Materials and methods Prostate 3-T MRI studies, reports, and clinical data from 623 patients (age 67.9 ± 8.2 years) were retrospectively analyzed and re-evaluated for the presence of EPFs and their clinical significance: E1—no finding or findings that have no clinical significance; E2—potentially significant findings; and E3—significant findings. Results Secondary reading identified 1236 EPFs in 593 patients (1.98 ± 1.13 EPFs per patient, no EPFs in 30 patients), from which 468 (37.8%) were mentioned in the original report. The most common findings included diverticulosis (44% of patients), hydrocele (34%), inguinal fat hernia (16%), and bladder wall trabecular hypertrophy (15%). There were 80 (6.5%) E2 EPFs and 30 (2.4%) E3 EPFs. From E3 EPFs, 10 (33%) were not originally reported.
Source: insightsimaging.springeropen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media? - 5 month(s) ago
European Radiology – To assess the visibility of clinically significant prostate cancer (PCA) lesions on the sequences multiparametric MRI of the prostate (mpMRI) and to evaluate whether the…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media? - 5 month(s) ago
European Radiology – To assess the visibility of clinically significant prostate cancer (PCA) lesions on the sequences multiparametric MRI of the prostate (mpMRI) and to evaluate whether the…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
European Radiology – This study aims to define consensus-based criteria for acquiring and reporting prostate MRI and establishing prerequisites for image quality. A total of 44 leading urologists…
Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 10A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements - 10 month(s) ago
Theranostics is the combination of two approaches—diagnostics and therapeutics—applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S. Food and Drug Administration (FDA) approval of lutetium 177 (177Lu) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE) and 177Lu–prostate-specific membrane antigen vector-based radionuclide therapies. The field of theranostics has imminent potential for emerging clinical applications. This article reviews critical areas of active clinical advancement in theranostics, including forthcoming clinical trials advancing FDA-approved and emerging radiopharmaceuticals, approaches to dosimetry calculations, imaging of different radionuclide therapies, expanded indications for currently used theranostic agents to treat a broader array of cancers, and emerging ideas in the field. Keywords: Molec
Source: pubs.rsna.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization? - European Radiology - 10 month(s) ago
Objectives To evaluate MRI diagnostic performance in detecting clinically significant prostate cancer (csPCa) in peripheral-zone PI-RADS 4 lesions, comparing those with clearly restricted diffusion (DWI-score 4), and those with equivocal diffusion pattern (DWI-score 3) and positive dynamic contrast-enhanced (DCE) MRI. Methods This observational prospective study enrolled 389 men referred to MRI…
Source: SpringerLinkCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/OZMygpHHV7 Categorizing PI-RADS 3 lesions in PI-RADS 3 and “3up” (enhancement) dilutes PI-RADS 4. Thus, only men with elevated PSAD or other risk factors should undergo biopsy. Further validation is needed. The EAU-guideline-table may help what to do in PI-RADS 3. https://t.co/uNB4RL1cBo
-
-
Mashup Score: 0Kanker.nl - we zijn er voor je | Kanker.nl - 11 month(s) ago
Kanker.nl is de plek voor betrouwbare informatie en ervaringen van anderen. Stel je vraag over kanker, ontmoet lotgenoten of schrijf je eigen blog. We zijn er voor je.
Source: Kanker.nlCategories: Hem/Oncs, Latest HeadlinesTweet
Register for our Course: https://t.co/lxxvpAYME1 See also: https://t.co/psPyQhL3KC https://t.co/MuTJSaIrPN